BioNTech gains rights to 4SC Discovery's potential cancer drugs

12/18/2012 | Genetic Engineering & Biotechnology News

4SC Discovery granted Germany-based BioNTech exclusive rights to market and commercialize its early-stage small molecule toll-like receptor agonists as immunotherapies for cancer. The research and licensing deal entitles 4SC to about $3.3 million upfront plus milestone and royalties. "Our goal is now to speed up and jointly develop a novel breakthrough therapy toward the market addressing the high medical need in the exciting field of cancer immunotherapy," 4SC Discovery Managing Director Daniel Vitt said.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC
Manager/Senior Manager, Health Economist
Avalere Health
Washington, DC